Galera Therapeutics amends Series B Preferred terms to allow board discretion to convert to common stock

Galera Therapeutics, Inc.

On Feb 12, 2026, Galera filed a Certificate of Amendment to its Series B Preferred Certificate of Designation.
Amendment grants the board sole discretion to convert Series B Preferred into common stock using the Conversion Ratio.
Amendment was approved by the board and by unanimous written consent of Series B holders.
No immediate conversion; board may elect to convert in whole or in part at a later date.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Galera Therapeutics, Inc.: Amended Series B Preferred Stock Certificate of Designation to allow board discretion to convert shares to Common Stock based on Conversion Ratio (effective 2026-02-12).

Change: charter amendment
Effective: 2026-02-12

Exact text from the filing

On February 12, 2026, Galera Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment (the “Amendment”) to the Certificate of Designation of Preferences, Rights, and Limitations of Series B Non-Voting Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of Delaware.

View on SEC.gov

Browse all governance changes →

Galera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-055919

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.